Articles - Page 58 of 92 - Drugs in Context

Tumor lysis syndrome in childhood malignancies

Wing Lum Cheung MBBS, MRCPCH, Kam Lun Hon MBBS, MD (CUHK), FAAP, FCCM, Cheuk Man Fung MBChB, MRCPCH, Alexander KC Leung MBBS, FRCPC, FRCP (UK & Irel), FRCPCH, FAAP

Article Type

Review

Published

25 Feb 2020

This review provides an update on the current understanding, evaluation, and management of tumor lysis syndrome in childhood malignancies.

Considerations for the US health-system pharmacist in a world of biosimilars

Andrea Zlatkus CRHC, Todd Bixby RPh, Kavitha Goyal MD

Article Type

Editorial

Published

25 Feb 2020

This editorial article provides an overview of the evolving healthcare landscape shaped by the entry of multiple biosimilars, including for a given reference product, and their impact on the healthsystem pharmacist with respect to formulary assessment, implementation, and education of various health-system stakeholders, including patients.

Efficacy and safety of photodynamic therapy with RLP068 for diabetic foot ulcers: a review of the literature and clinical experience

Felicia Pantò MD, Liboria Adamo BSc, Carla Giordano MD, Carmelo Licciardello MD

Article Type

Review

Published

10 Feb 2020

This is the second part of a literature review concerning diabetic foot ulcers (DFUs) and the use of antimicrobial photodynamic therapy (PDT). It focuses on the Zn(II)phthalocyanine derivative RLP608.

Management of type 2 diabetes: consensus of diabetes organizations

Elaena Quattrocchi BS, PharmD, FASHP, CDE, Tamara Goldberg BS, PharmD, BCPS, Nino Marzella BS, MS, PharmD

Article Type

Review

Published

27 Jan 2020

This article reviews the recommendations of different diabetes organizations for achieving glycemic control.

Efficacy and safety of a GABAergic drug (Gamalate® B6): effects on behavior and cognition in young adults with borderline-to-mild intellectual developmental disabilities and ADHD

Ramón Novell MD, Susanna Esteba-Castillo PhD, Emili Rodriguez PhD

Article Type

Original Research

Published

23 Jan 2020

Gamalate B6 was evaluated in patients
with borderline intellectual functioning or mild intellectual
development disability and found to be effective and well tolerated for ADHD and challenging behavior.